Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Feb 5, 2025
Date Accepted: Jun 12, 2025

The final, peer-reviewed published version of this preprint can be found here:

The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study

Bae S, Kim JS, Lee MWL, Kim GH, Kim YI, Jung WT, Baik GHB, Kim BJ, Lee J, Suh M, Kim JG

The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study

JMIR Res Protoc 2025;14:e72228

DOI: 10.2196/72228

PMID: 40663770

PMCID: 12308161

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Cost-effectiveness of adding Helicobacter pylori screening to the National Gastric Cancer Screening Program in Korea

  • Seowoo Bae; 
  • Joon Sung Kim; 
  • Moon Won Lee Lee; 
  • Gwang Ha Kim; 
  • Young-Il Kim; 
  • Woon Tae Jung; 
  • Gwang Ho Baik Baik; 
  • Beom Jin Kim; 
  • Joongyub Lee; 
  • Mina Suh; 
  • Jae Gyu Kim

ABSTRACT

Background:

Helicobacter pylori (H. pylori) screening with eradication reduces gastric cancer incidence and mortality.

Objective:

This study evaluated the cost-effectiveness of incorporating H. pylori screening into Korea's National Gastric Cancer Screening Program.

Methods:

A Markov model was developed to compare two strategies: (1) endoscopy screening every two years starting at age 40 (conventional screening), and (2) H. pylori testing and eradication therapy at age 40, followed by continuous endoscopy screening. The primary outcome is the Incremental Cost-Utility Ratio (ICUR), calculated by dividing incremental cost by incremental quality-adjusted life year (QALY) between the two strategies. Sensitivity analysis identified the most influential variables for cost-effectiveness.

Results:

The primary outcome parameter is the cost-effectiveness of adding H.pylori testing to the current NCSP, which will be expressed as ICUR. Costs and utility will be discounted at an annual ra: This study determined that introducing H. pylori testing and eradication therapy into the National Gastric Cancer Screening Program is a more cost-effective strategy for reducing gastric cancer risk than a conventional endoscopy-based cancer screening program. te of 4.5%. ICUR threshold will be set at KRW 50 million, which is South Korea’s Gross Domestic Product (GDP) per capita.

Conclusions:

This study determined that introducing H. pylori testing and eradication therapy into the National Gastric Cancer Screening Program is a more cost-effective strategy for reducing gastric cancer risk than a conventional endoscopy-based cancer screening program. Clinical Trial: None


 Citation

Please cite as:

Bae S, Kim JS, Lee MWL, Kim GH, Kim YI, Jung WT, Baik GHB, Kim BJ, Lee J, Suh M, Kim JG

The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study

JMIR Res Protoc 2025;14:e72228

DOI: 10.2196/72228

PMID: 40663770

PMCID: 12308161

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.